O-0032PHASE III RANDOMIZED, PLACEBO(PL)-CONTROLLED, DOUBLE-BLIND STUDY OF INTRAVENOUS CALCIUM/MAGNESIUM (CAMG) TO PREVENT OXALIPLATIN-INDUCED SENSORY NEUROTOXICITY (SNT), N08CB: AN ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY STUDY1